drugset / Trial / NCT05739942
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will investigate different doses of \[177Lu\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \[177Lu\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma as single agent, to identify the recommended dose and to also explore the safety of the PET imaging agent \[68Ga\]Ga-NeoB and characterize its uptake in the tumor area.
Timeline
- Start
- 2024-05-15
- Primary completion
- 2028-11-08
- Completion
- 2028-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [177Lu]Lu-NeoB | Other / unclassified | — | Other |
| Subject | [68Ga]Ga-NeoB | Diagnostic / imaging agent | — | Other |